Efficacy of afoxolaner (NexGard®) against natural infestations with Trichodectes canis in dogs under field conditions.
Afoxolaner
Chewing lice
Efficacy assessment
Trichodectes canis
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
07 Sep 2022
07 Sep 2022
Historique:
received:
25
06
2022
accepted:
02
08
2022
entrez:
7
9
2022
pubmed:
8
9
2022
medline:
11
9
2022
Statut:
epublish
Résumé
Trichodectes canis is a small chewing louse found globally that primarily infests dogs. Limited information is available on the efficacy of isoxazolines against infestation with the chewing louse. In the present study, we evaluated the efficacy of afoxolaner, an isoxazoline class compound, in naturally infested domestic dogs. The field study was carried out in Romania. Between September 2021 and December 2021, 43 dogs with confirmed T. canis infestation were included in the study. On the day of the inclusion (day 0), each animal was clinically examined and randomly treated with a control product labeled for use against lice [fipronil-(S)-methoprene combination (Frontline Combo®; Boehringer Ingelheim)] or with the investigational product [chewable tablets containing afoxolaner (NexGard®; isoxazoline)]. Each animal was evaluated for the presence of lice at 15 and 30 days post-inclusion. Of the 48 dogs initially included in the study, 43 completed the treatment period [18 in the control group (CG) and 25 in the investigational group (IG)]. At day 14, no living T. canis lice were detected on the dogs in either group. At day 14, dead lice were detected in four dogs in the IG, while eggs were present in two dogs in the IG and in one dog in the CG. At day 30, no lice were detected in either group, while eggs were still present in one dog in the CG. These results suggest that afoxolaner is a feasible treatment option against chewing lice in dogs, providing 100% curative efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Trichodectes canis is a small chewing louse found globally that primarily infests dogs. Limited information is available on the efficacy of isoxazolines against infestation with the chewing louse. In the present study, we evaluated the efficacy of afoxolaner, an isoxazoline class compound, in naturally infested domestic dogs.
METHODS
METHODS
The field study was carried out in Romania. Between September 2021 and December 2021, 43 dogs with confirmed T. canis infestation were included in the study. On the day of the inclusion (day 0), each animal was clinically examined and randomly treated with a control product labeled for use against lice [fipronil-(S)-methoprene combination (Frontline Combo®; Boehringer Ingelheim)] or with the investigational product [chewable tablets containing afoxolaner (NexGard®; isoxazoline)]. Each animal was evaluated for the presence of lice at 15 and 30 days post-inclusion.
RESULTS
RESULTS
Of the 48 dogs initially included in the study, 43 completed the treatment period [18 in the control group (CG) and 25 in the investigational group (IG)]. At day 14, no living T. canis lice were detected on the dogs in either group. At day 14, dead lice were detected in four dogs in the IG, while eggs were present in two dogs in the IG and in one dog in the CG. At day 30, no lice were detected in either group, while eggs were still present in one dog in the CG.
CONCLUSION
CONCLUSIONS
These results suggest that afoxolaner is a feasible treatment option against chewing lice in dogs, providing 100% curative efficacy.
Identifiants
pubmed: 36071527
doi: 10.1186/s13071-022-05428-y
pii: 10.1186/s13071-022-05428-y
pmc: PMC9450229
doi:
Substances chimiques
Isoxazoles
0
Naphthalenes
0
afoxolaner
02L07H6D0U
Types de publication
Journal Article
Randomized Controlled Trial, Veterinary
Langues
eng
Sous-ensembles de citation
IM
Pagination
317Informations de copyright
© 2022. The Author(s).
Références
Parasite. 2016;23:14
pubmed: 27012161
Bioorg Med Chem. 2021 Jan 15;30:115934
pubmed: 33360575
Parasite. 2018;25:63
pubmed: 30516132
Vet Parasitol. 2013 Mar 31;193(1-3):245-51
pubmed: 23290278
J Vet Pharmacol Ther. 2017 Jan;40(1):35-43
pubmed: 27604405
Vet Parasitol. 2014 Apr 2;201(3-4):198-203
pubmed: 24629431
Vet Parasitol. 2014 Apr 2;201(3-4):190-7
pubmed: 24685320
Parasite. 2016;23:26
pubmed: 27317462
Biomedica. 2021 Dec 15;41(4):756-772
pubmed: 34936259
Parasit Vectors. 2017 Sep 18;10(1):426
pubmed: 28923117
Vet Parasitol. 2014 Apr 2;201(3-4):179-89
pubmed: 24631502
Vet Parasitol. 2002 Jul 29;107(1-2):127-36
pubmed: 12072220
J Vet Pharmacol Ther. 2017 Oct;40(5):447-453
pubmed: 27891622
Vet Rec. 2003 Feb 22;152(8):234-7
pubmed: 12625538
Parasitol Res. 1999 Apr;85(4):347-8
pubmed: 10099020
Korean J Parasitol. 2008 Mar;46(1):23-7
pubmed: 18344673
BMC Vet Res. 2008 Dec 09;4:49
pubmed: 19068110
Vet Parasitol. 2020 Apr;280:109065
pubmed: 32203695
Parasitol Res. 2012 Feb;110(2):769-73
pubmed: 21881947
Parasit Vectors. 2012 May 30;5:102
pubmed: 22647530
Vet Rec. 1996 Jul 27;139(4):95
pubmed: 8843643
Vet Dermatol. 2019 Apr;30(2):167-e50
pubmed: 30556631
Vet Ther. 2001 Spring;2(2):135-9
pubmed: 19753706
Parasitol Res. 2009 Nov;105(6):1577-87
pubmed: 19690887
Vet Dermatol. 2015 Feb;26(1):70-1
pubmed: 25399525
Rev Bras Parasitol Vet. 2012 Apr-Jun;21(2):179-83
pubmed: 22832763
J Vet Pharmacol Ther. 2022 Jan;45(1):1-15
pubmed: 33733534
Parasit Vectors. 2018 Sep 10;11(1):506
pubmed: 30201031
Vet Parasitol. 2021 Dec;300:109607
pubmed: 34735846